Customize your JAMA Network experience by selecting one or more topics from the list below.
To the Editor.—
We are writing in response to the BRIEF REPORT entitled "Superior Vena Cava Syndrome due to Non-Small-cell Lung Cancer" by Citron et al.1 These authors report successful therapy for the superior vena cava (SVC) syndrome in their patients using combined chemotherapy. It has been reported that cisplatin regimens, as used in this report, can lead to responses in approximately 40% to 50% of treated patients.2,3 This is certainly far less than the reported effectiveness of radiation therapy, which has a reported response rate of 80% to 90% in patients with the SVC syndrome.4Although the report by Citron et al is of interest, a comparison of these disparate forms of treatment for SVC syndrome remains to be properly studied in patients with non-small-cell lung cancer.On the basis of this brief report, we believe that great caution should be observed. From the available studies
Rosenbloom BE, Rosenfelt FP. Treatment of Superior Vena Cava Syndrome. JAMA. 1984;251(9):1162. doi:10.1001/jama.1984.03340330024014
Coronavirus Resource Center
Create a personal account or sign in to: